Perugia

• VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM … Recruiting
  2024-520119-41-00 4 2023-01-15 Previously untreated patients with diagnosis of HCL
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: … Recruiting
  2024-515981-14-00 5 2022-12-14 Gastric adenocarcinoma with peritoneal metastases
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k … Recruiting
  2023-510240-20-00 4 2022-10-05 Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with … Recruiting
  2024-514687-33-00 4 2021-12-21 Previously Untreated Chronic Lymphophatic Leukaemia
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• “A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in surgically resectable, high risk stage II … Recruiting
  2024-515204-39-00 4 2021-02-10 surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c … Recruiting
  2023-505901-17-00 5 2020-04-24 Acute Myeloid Leukemia (LMA) with FLT3 mutation
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended recruitment
  2024-512180-31-00 4 2025-03-14 Oligometastatic renal cell carcinoma
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended recruitment
  2024-512946-41-00 5 2025-03-05 Menstrual Migraine
• A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) Ended recruitment
  2024-515089-15-00 5 2025-02-28 active non-infectious uveitis (intermediate uveitis, posterior uveitis
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE … Ended recruitment
  2024-520121-36-00 4 2025-01-28 The following categories of HCL patients needing anti-leukemic treatme

Showing 121–144 of 270 trials